Vertex’s Cystic Fibrosis Franchise Has Multiple Jump Points In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
Kalydeco revenues should build momentum this year, and Vertex’s franchise could see an even sharper uptick should its combination products reach the market.